Proton Therapy Did Not Extend Liver Cancer Survival
A clinical trial found that proton radiation offered no survival advantage over standard photon therapy for liver cancer.
Updated on Sept. 29, 2026 in Cancer
Live Poll
Would you trust a new therapy if clinical trials show it performs similarly to traditional treatments?
The NRG-GI003 clinical trial, which concluded enrollment in January 2026, found that proton therapy did not extend survival in patients with advanced liver cancer. Participants receiving photon therapy showed a median survival of nearly 55 months compared to 24 months in the proton therapy group.
Why it matters
The study highlights critical differences in treatment outcomes, as medical professionals seek to determine the most effective radiation methods for liver cancer patients. Identifying which patient subgroups benefit from specific therapies remains a vital goal for oncology researchers.
The trial involved 115 participants with a median age of 72 and a median tumor size of 5.1 centimeters. Proton therapy resulted in an 11% rate of severe treatment-related side effects, compared to 24% for those receiving photon therapy.
The players
NRG-GI003
This is a multi-center clinical research trial designed to evaluate radiation therapy efficacy for patients with advanced liver cancer.
The details
Researchers randomly assigned participants to receive radiation in either five or 15 sessions with doses tailored to their individual needs. While proton therapy delivered a lower median radiation dose of 8.5 Gy to healthy liver tissue compared to 12.8 Gy with photons, it did not lead to improved overall survival rates.
Timeline
Trial enrollment began in June 2017.
Trial enrollment concluded in January 2026.
Progression-free survival and recurrence rates were measured at 24 months.
The Big Picture
This study updates the data generated by the NRG-GI003 clinical trial, which remains the benchmark for evaluating radiotherapy techniques in liver cancer patients. These findings provide a definitive assessment of proton versus photon efficacy within this established research framework.
Patients may discuss these findings with their oncologists to understand how different radiation protocols impact potential side effects and treatment intensity. The study underscores that while photon therapy may involve higher doses to healthy tissue, it remains a standard and effective clinical option.
The takeaway
These results provide important clarity for patients choosing between different radiation technologies for advanced liver cancer. Researchers will continue to analyze the trial data to see if certain patient groups might still find proton therapy beneficial for their specific needs.
Further reading
For more information on current treatment standards, visit the Cancer section.
Source note: This article includes information reported by Curetoday.
Live Poll
Would you trust a new therapy if clinical trials show it performs similarly to traditional treatments?
